TLDR Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.
The document titled "Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The 'Gabrin sign'" presents evidence that suggests a link between androgen sensitivity and severe symptoms of COVID-19. The study examined 175 individuals with confirmed COVID-19 who were admitted to hospitals in Madrid, Spain. The study found that 67% of the patients had androgenetic alopecia, with a higher frequency in men than women. The study suggests that larger studies should be conducted to validate the association between androgen sensitivity and COVID-19 severity. The study also proposes the use of the term "Gabrin sign" to visually identify patients at higher risk for severe symptoms after COVID-19 infection. However, the study acknowledges limitations such as the small sample size and lack of a control group.View this study on jaad.org →
Male pattern hair loss could hint at androgens affecting COVID-19 severity.
FPHL affects hair density and diameter, causing visible hair loss in older women.